Figure 4.

 Serum amyloid P component (SAP) does not behave as an acute phase protein. (A) SAP, C reactive protein, and serum amyloid A (SAA) responses in a patient with breast cancer treated for seven days with recombinant interleukin 6 (rhIL-6) at a dose of 20 µg/kg/day. Even though a significant increase in C reactive protein (from18 to 395 mg/l on day 3) and an even more pronounced increase in SAA (from 11 to 770 mg/l on day 3) occurred, SAP levels hardly changed. (B) SAP levels of the same patient in more detail, showing a decline in SAP up to day 3, at the maximum of the acute phase response, and a slight increase thereafter.